EU Oncology Biosimilars
Oct 26, 2018

IQVIA research identified that the total EU5 oncology market grew to $25 bn in 2017, and the launch of biosimilars over the next few years will make new drugs more accessible to patients. The information is for EU5 countries (France, Germany, Italy, Spain and U.K.).

You may also be interested in
Contact Us
Contact Us

Email Us

Get in touch today to discover the right solutions for you.

Call Us

We are pleased to speak with you during our standard business hours.

U.S. Toll-Free only
+1 866 267 4479

For international call please find a number in our toll-free list.